Boehringer Ingelheim (BI) announced today that its adalimumab biosimilar, Cyltezo, has been granted marketing authorization by the European Commission to treat multiple rheumatic diseases after having received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use in September 2017.
Boehringer Ingelheim (BI) announced today that its adalimumab biosimilar, Cyltezo, has been granted marketing authorization by the European Commission (EC) to treat multiple rheumatic diseases, after having received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in September 2017.
The approval “…marks a significant step forward for us in offering effective and more affordable treatment options for patients with chronic inflammatory diseases,” said Ivan Blanarik, senior vice president and head of therapeutic area biosimilars at BI. “We believe biosimilars will be a key contributor to the future sustainability of healthcare systems around the world,” he added.
Cyltezo's marketing approval comes on the heels of last week’s announcement of 1-year data from BI’s VOLTAIRE-RA trial, which showed that the biosimilar had no clinically meaningful differences in safety, efficacy, or immunogenicity from the reference Humira in patients who had moderate to severe RA.
In addition to earning the EC’s marketing authorization, Cyltezo also gained FDA approval in August 2017. Currently, it is unclear when the drug may reach the marketplace, as BI is currently engaged in patent litigation with AbbVie.
While litigation continues, BI is undertaking an interchangeability study for its drug in an effort to gain an FDA designation of interchangeability with the reference Humira. BI’s study will compare pharmacokinetics and clinical outcomes of 240 patients with moderate to severe chronic plaque psoriasis who receive the reference adalimumab continuously versus patients with the same diagnosis who switch multiple times between the reference and Cyltezo.
While the FDA has not yet finalized its guidance on demonstrating a biosimilar’s interchangeability with its reference, the agency’s draft guidance holds that interchangeable status will only be granted in cases in which the risk (in terms of safety or diminished efficacy) of switching between the reference and the biosimilar is no greater than the risk of using the reference product alone. The agency expects manufacturers seeking interchangeable status to include data from switching studies, conducted in sensitive populations, that include at least 3 switches.
Part 3: BioRationality—FDA Webinar on Biosimilars Efficacy Testing Marks Major Step Forward
September 20th 2023In the final part of a 3-part series, Sarfaraz K. Niazi, PhD, gives his take on the FDA's recent workshop dedicated to streamlining biosimilar development and his opinion on what the industry can learn from the webinar presenters.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AAM Report: Generics and Biosimilars Generate $408 Billion in 2022
September 12th 2023A report from the Association for Accessible Medicines (AAM) highlighted the value of biosimilars and generics, revealing that lower-cost versions of originator products accumulated $408 billion for the US health care system in 2022.
Regulatory Updates From Around the Globe Provide Hope for Biosimilars
September 9th 2023An approval in Australia and positive recommendations for 2 biosimilars in Europe bring hope for more affordable biologics around the world. However, another settlement for a US ustekinumab biosimilar showcases that some barriers remain.
2 Clarke Drive
Cranbury, NJ 08512